Clinic
Eastern Niagara Hospital, INC
Eastern Niagara Hospital, INC was paid $5.05M by Medicaid between Jan 2018 and Jun 2023, across 136 billing codes. Its largest line is 99283, emergency room visit (moderate) — 14% of everything it billed.
33Billing provider infoEASTERN NIAGARA HOSPITAL, INC
LOCKPORT, NY 14094
LOCKPORT, NY 14094
33aNPI1063400539assigned 10/10/2005
33bProvider typeEnd-Stage Renal Disease (ESRD) Treatment Clinic/Center
28Total paid$5.05M
24GClaims157,686
24DCodes billed136
24AFirst – last monthJan 2018 – Jun 2023
Compared with peers
Next to other End-Stage Renal Disease (ESRD) Treatment Clinic/Center providers in New York
Rank by total paid#26 of 231
Median peer was paid$774K
This provider vs. median6.5×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 3,220 | $46K | |
| 2019 | 20,432 | $576K | |
| 2020 | 36,533 | $1.13M | |
| 2021 | 41,900 | $1.42M | |
| 2022 | 39,353 | $1.31M | |
| 2023 | 16,248 | $575K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 14% | 6,075 | 5,841 | $729K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 12% | 4,556 | 4,365 | $596K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 11% | 7,880 | 7,715 | $560K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 7.8% | 6,641 | 6,529 | $393K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 7.7% | 3,398 | 3,293 | $387K |
| 70450 | Computed tomography, head or brain; without contrast material | 3.9% | 832 | 812 | $199K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 3.8% | 462 | 456 | $192K |
| 80053 | Comprehensive metabolic panel | 3.7% | 11,460 | 10,429 | $187K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.6% | 817 | 803 | $184K |
| 96361 | Intravenous infusion, hydration; each additional hour | 2.7% | 732 | 716 | $137K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 2.6% | 1,190 | 1,163 | $130K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 2.6% | 915 | 891 | $129K |
124 more codes
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 2.2% | 1,019 | $110K |
| 99203 | Doctor's office visit, new patient (routine) | 1.8% | 891 | $91K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.6% | 360 | $81K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 1.4% | 2,059 | $73K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | 1.1% | 582 | $56K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.0% | 3,135 | $51K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 4,107 | $48K |
| 80061 | Lipid panel | <1% | 4,161 | $42K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 3,026 | $38K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,661 | $31K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 540 | $28K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 717 | $28K |
| 36415 | Collection of venous blood by venipuncture | <1% | 12,052 | $27K |
| 83880 | <1% | 479 | $24K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 743 | $23K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 2,097 | $23K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,103 | $21K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 9,455 | $20K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 192 | $20K |
| 99222 | Initial hospital care, per day, moderate complexity | <1% | 208 | $20K |
| 84439 | <1% | 2,440 | $19K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 798 | $19K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 248 | $17K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 2,001 | $16K |
| 12001 | <1% | 60 | $16K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,389 | $16K |
| 82803 | <1% | 958 | $15K | |
| G0378 | Hospital observation service, per hour | <1% | 40 | $14K |
| 99201 | <1% | 144 | $14K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,323 | $14K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 245 | $13K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 742 | $13K |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 392 | $12K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 639 | $11K |
| 82607 | <1% | 802 | $9K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,660 | $9K |
| 81001 | <1% | 3,650 | $9K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 13 | $9K |
| 99223 | Prolong inpt eval add15 m | <1% | 73 | $8K |
| 84153 | <1% | 422 | $8K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 3,581 | $7K |
| 81025 | <1% | 2,340 | $6K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 43 | $6K |
| 90791 | Psychiatric diagnostic evaluation | <1% | 40 | $4K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 2,934 | $4K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 13 | $4K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 25 | $4K |
| 85027 | <1% | 1,788 | $4K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 552 | $3K |
| 99238 | Hospital discharge day management, 30 minutes or less | <1% | 88 | $3K |
| 82043 | <1% | 664 | $3K | |
| 84702 | <1% | 596 | $3K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 838 | $3K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 167 | $3K |
| 0012A | <1% | 66 | $3K | |
| J1670 | Injection, tetanus immune globulin, human, up to 250 units | <1% | 13 | $3K |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 324 | $2K |
| 82570 | <1% | 509 | $2K | |
| 85610 | <1% | 1,328 | $2K | |
| 99233 | Hospital visit by a doctor, follow-up day (complex) | <1% | 45 | $2K |
| 81003 | <1% | 2,575 | $2K | |
| 0011A | <1% | 71 | $2K | |
| 76536 | <1% | 92 | $2K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 123 | $2K |
| 72100 | <1% | 185 | $2K | |
| 82746 | <1% | 165 | $2K | |
| 80162 | <1% | 107 | $2K | |
| 73630 | <1% | 598 | $2K | |
| 71045 | Radiologic examination, chest; single view | <1% | 1,735 | $2K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 3,962 | $2K |
| 86803 | <1% | 168 | $1K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 1,805 | $1K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 14 | $1K |
| 83735 | <1% | 1,134 | $1K | |
| 82728 | <1% | 91 | $1K | |
| 72110 | <1% | 75 | $1K | |
| 73030 | <1% | 182 | $1K | |
| 74018 | <1% | 303 | $1K | |
| 83690 | <1% | 1,990 | $1K | |
| 73130 | <1% | 491 | $1K | |
| 84484 | <1% | 2,083 | $998.87 | |
| 87186 | <1% | 504 | $978.32 | |
| 85730 | <1% | 674 | $953.97 | |
| 83540 | <1% | 196 | $894.01 | |
| 73610 | <1% | 469 | $847.41 | |
| 90715 | <1% | 39 | $840.59 | |
| 86901 | <1% | 46 | $796.50 | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 1,594 | $775.13 |
| 83550 | <1% | 155 | $696.46 | |
| 76641 | <1% | 36 | $683.70 | |
| 85651 | <1% | 419 | $645.94 | |
| 84481 | <1% | 71 | $625.99 | |
| 84403 | <1% | 25 | $615.94 | |
| 86850 | <1% | 29 | $612.44 | |
| 86900 | <1% | 46 | $531.67 | |
| 87340 | <1% | 52 | $501.46 | |
| 73564 | <1% | 97 | $490.04 | |
| 87070 | <1% | 871 | $410.17 | |
| 82248 | <1% | 95 | $397.07 | |
| 85007 | <1% | 901 | $342.36 | |
| 86780 | <1% | 25 | $290.49 | |
| 83605 | <1% | 808 | $254.95 | |
| 73110 | <1% | 109 | $219.35 | |
| 86703 | <1% | 16 | $199.22 | |
| 83655 | <1% | 13 | $194.35 | |
| 80076 | <1% | 13 | $184.41 | |
| 73502 | <1% | 12 | $170.51 | |
| 86038 | <1% | 28 | $137.88 | |
| 87077 | <1% | 51 | $133.95 | |
| 87899 | <1% | 87 | $121.90 | |
| 96376 | <1% | 313 | $116.00 | |
| 82948 | <1% | 667 | $113.69 | |
| 87088 | <1% | 35 | $107.44 | |
| 82150 | <1% | 152 | $102.61 | |
| 86140 | <1% | 26 | $102.53 | |
| P9604 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge | <1% | 353 | $100.17 |
| 73562 | <1% | 13 | $96.78 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 818 | $60.36 |
| 85379 | <1% | 88 | $50.90 | |
| 87147 | <1% | 19 | $24.77 | |
| P9603 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated miles actually travelled | <1% | 93 | $6.88 |
| 87420 | 0% | 31 | $0.00 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 0% | 51 | $0.00 |
| J7609 | Albuterol, inhalation solution, compounded product, administered through dme, unit dose, 1 mg | 0% | 59 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialICKOWSKI, MICHAEL (CHIEF FINANCIAL OFFICER)
| Provider | Location | Paid |
|---|---|---|
| Indiana Regional Medical Center | Indiana, PA | $10.63M |
| Eastern Niagara Medical Group | Lockport, NY | $85K |
| Indiana Regional Medical Center | Indiana, PA | $84K |
| Eastern Niagara Hospital INC | Lockport, NY | $9K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.